Use access key #2 to skip to page content.

Closing DNDN (Dendreon) underperform



March 07, 2008 – Comments (2) | RELATED TICKERS: DNDNQ

I don't have any specific reason for ending this underperform today, except that I was waiting for it to go below 5. We're now at the level Dendreon likes to bottom feed at before spiking on some perceived positive news. I'm going to resist the temptation to be greedy, take my points, and wait for another spike in the first half of 2008 before shorting it again going into IMPACT results.

2 Comments – Post Your Own

#1) On March 07, 2008 at 1:38 PM, DemonDoug (31.13) wrote:

ZZ: I'd like to encourage you to post more, especially if anything new comes under your radar screen.  Biotech is something that many people are interested in but few understand, and I'd like to get a better understanding with more discussion myself.

Personally, I hold DNDN long in my portfolio.  I really feel the FDA and special interests screwed them last year.  Any comment on this would be appreciated.

It would appear that going short on biotechs seems like a generally good play at almost any time.  So many of them don't make any money and very few ever do.

Report this comment
#2) On March 10, 2008 at 1:08 PM, zzlangerhans (99.80) wrote:

Thanks for the encouragement. Hopefully people will be able to do well by employing a strategy of carefully reviewing my picks and then buying in the opposite direction.If so, you'll make a lot of money on Dendreon because my feelings on this company are extremely negative. The company seems to encourage political pressure to approve a drug that simply has not been shown to work. I just don't think cancer immunotherapy is ready for the big time based on the performance of phase III trials so far. But if you can time the IMPACT results pretty well, it's a great opportunity for an options spread trade.

Report this comment

Featured Broker Partners